Q-omics provides the consensus-scored FBXO10 profile across patient tissues and cancer cell-line models. FBXO10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FBXO10 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, FBXO10 RNA expression shows 19,868 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LIHC, and UVM as cancer lineages where FBXO10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO10 survival associations across molecular data types. FBXO10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO10 RNA expression–survival associations across cancer types. High FBXO10 expression shows unfavorable associations in ACC, UVM, LIHC, MESO and COAD, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FBXO10 RNA expression.
This table summarizes FBXO10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXO10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO10 shows lower tumor expression in THCA, KIRC, BRCA and PAAD and higher tumor expression in LIHC and UCEC. The LIHC box plot shows higher FBXO10 RNA expression in tumor versus normal tissue (log2 FC = +0.827, t-test p < 0.001).
This table shows molecular features associated with FBXO10 in patient tissues and cancer cell lines. In patient samples, FBXO10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
